2018年USPSTF指南更新后前列腺癌PSA筛查中的共享决策
该研究基于2015与2018年美国国家健康访谈调查数据,纳入50岁及以上男性10926人,分析2018年USPSTF推荐前后PSA筛查与共享决策的变化。结果显示PSA筛查率无显著变化,但共享决策率显著上升,尤其在55-69岁男性中。
要点
- 2015至2018年PSA筛查率无显著变化
- 共享决策率显著上升,55-69岁男性最明显
- 70岁以上男性PSA筛查率亦无显著变化
核心结论
- 2015至2018年间PSA-based前列腺癌筛查无显著增加,但共享决策显著增加,尤其在55-69岁男性中。
研究设计与样本
- 回顾性横断面研究,使用2015和2018年美国国家健康访谈调查数据,纳入50岁及以上男性10926人。
主要发现
- 常规PSA筛查率从2015年34.3%到2018年上半年35.4%、下半年36.0%,趋势P=0.57。
- 70岁及以上男性PSA筛查趋势P=0.98。
- 50岁及以上男性共享决策率从2015年30.5%升至2018年上半年33.6%、下半年36.7%,趋势P=0.002。
- 55-69岁男性共享决策率分别为31.6%、36.9%、40.2%,趋势P=0.001。
临床怎么用
- 在55-69岁男性PSA筛查中应常规实施共享决策,讨论筛查利弊。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous study reported shared decision making was underused in PSA-based prostate cancer screening. In mid-2018, the US Preventive Service Task Force recommended shared decision making (SDM) before PSA-based prostate cancer screening among men aged 55-69 year while remained against PSA testing in men aged 70 or older. The objective of this study is to examine recent changes in SDM and prostate cancer screening following recent USPSTF recommendations. METHODS: A retrospective cross-sectional study among men aged 50 years or older were conducted using 2015 and 2018 National Health Interview Survey data (n = 10,926). Outcomes included self-reported PSA testing for prostate cancer screening last year, and if yes, whether respondent ever had a discussion with the healthcare provider about its advantages and disadvantages. Analyses were stratified by respondent's age (50-54 vs. 55-69 vs. 70+). RESULTS: Routine PSA screening rates remained stable from 34.3% in 2015 to 35.4% in first half of 2018, and 36.0% in second half of 2018 (p trend = 0.57). A similar pattern was found in men ≥70 years (p trend = 0.98). Receipt of SDM increased in men aged ≥50 years from 30.5% in 2015 to 33.6% in first half of 2018, and 36.7% in second half of 2018 (p trend = 0.002). The increase was most prominent in men aged 55 to 69 years (31.6, 36.9, and 40.2% in 2015, first half of 2018 and second half of 2018 respectively; p trend = 0.001). CONCLUSIONS: Between 2015 and 2018, there was no significant increase in the PSA-based prostate cancer screening. However, a significant increasing trend in SDM was observed, especially in men aged 55-69 years.
引用
- Jiang C, Fedewa SA, Wen Y, et al. Shared decision making and prostate-specific antigen based prostate cancer screening following the 2018 update of USPSTF screening guideline. Prostate Cancer Prostatic Dis. 2020. PMID: 32296126. doi:10.1038/s41391-020-0227-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。